| Kristen Caviness Sihler, MD | |
|
200 Hawkins Dr, Iowa City, IA 52242-1009 | |
| (319) 356-2902 | |
| (319) 356-8378 |
| Full Name | Kristen Caviness Sihler |
|---|---|
| Gender | Female |
| Speciality | General Surgery |
| Experience | 26 Years |
| Location | 200 Hawkins Dr, Iowa City, Iowa |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023194990 | NPI | - | NPPES |
| 30209989 | Medicaid | NH |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Iowa Hospital & Clinics | Iowa city, IA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| State University Of Iowa | 7618884230 | 1476 |
News Archive
A breast cancer vaccine developed at Washington University School of Medicine in St. Louis is safe in patients with metastatic breast cancer, results of an early clinical trial indicate. Preliminary evidence also suggests that the vaccine primed the patients' immune systems to attack tumor cells and helped slow the cancer's progression.
b3 bio inc. today announced that it has signed an agreement with Roche to source and develop innovative early stage technologies that could result in potential therapeutic benefits for patients. Roche will have certain rights for further development and/or commercialization of such technologies. As part of this agreement, Roche will increase its equity investment in b3 bio as well as providing development funds.
A recent study funded by Centers for Disease Control and Prevention Epicenters Program and published in Infection Control and Hospital Epidemiology ( Deverick H. Anderson , M.D., MPH et al., 2013) supports and expands on previously published studies confirming the effectiveness of an automated UV-C-emitting device to combat the pathogens Clostridium difficile (C. diff.), vancomycin-resistant enterococci (VRE) and Acinetobacter spp. – some of the common culprits of health care-associated infections drawing increased attention for hospitals across the country.
Regenerx Biopharmaceuticals Inc. has announced the results of its Phase II clinical trial evaluating the safety and wound-healing efficacy of RGN-137 for the treatment of patients with venous stasis ulcers.
› Verified 5 days ago
| Entity Name | State University Of Iowa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477554814 PECOS PAC ID: 7618884230 Enrollment ID: O20031107000060 |
News Archive
A breast cancer vaccine developed at Washington University School of Medicine in St. Louis is safe in patients with metastatic breast cancer, results of an early clinical trial indicate. Preliminary evidence also suggests that the vaccine primed the patients' immune systems to attack tumor cells and helped slow the cancer's progression.
b3 bio inc. today announced that it has signed an agreement with Roche to source and develop innovative early stage technologies that could result in potential therapeutic benefits for patients. Roche will have certain rights for further development and/or commercialization of such technologies. As part of this agreement, Roche will increase its equity investment in b3 bio as well as providing development funds.
A recent study funded by Centers for Disease Control and Prevention Epicenters Program and published in Infection Control and Hospital Epidemiology ( Deverick H. Anderson , M.D., MPH et al., 2013) supports and expands on previously published studies confirming the effectiveness of an automated UV-C-emitting device to combat the pathogens Clostridium difficile (C. diff.), vancomycin-resistant enterococci (VRE) and Acinetobacter spp. – some of the common culprits of health care-associated infections drawing increased attention for hospitals across the country.
Regenerx Biopharmaceuticals Inc. has announced the results of its Phase II clinical trial evaluating the safety and wound-healing efficacy of RGN-137 for the treatment of patients with venous stasis ulcers.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kristen Caviness Sihler, MD 200 Hawkins Dr, Iowa City, IA 52242-1009 Ph: (319) 356-2902 | Kristen Caviness Sihler, MD 200 Hawkins Dr, Iowa City, IA 52242-1009 Ph: (319) 356-2902 |
News Archive
A breast cancer vaccine developed at Washington University School of Medicine in St. Louis is safe in patients with metastatic breast cancer, results of an early clinical trial indicate. Preliminary evidence also suggests that the vaccine primed the patients' immune systems to attack tumor cells and helped slow the cancer's progression.
b3 bio inc. today announced that it has signed an agreement with Roche to source and develop innovative early stage technologies that could result in potential therapeutic benefits for patients. Roche will have certain rights for further development and/or commercialization of such technologies. As part of this agreement, Roche will increase its equity investment in b3 bio as well as providing development funds.
A recent study funded by Centers for Disease Control and Prevention Epicenters Program and published in Infection Control and Hospital Epidemiology ( Deverick H. Anderson , M.D., MPH et al., 2013) supports and expands on previously published studies confirming the effectiveness of an automated UV-C-emitting device to combat the pathogens Clostridium difficile (C. diff.), vancomycin-resistant enterococci (VRE) and Acinetobacter spp. – some of the common culprits of health care-associated infections drawing increased attention for hospitals across the country.
Regenerx Biopharmaceuticals Inc. has announced the results of its Phase II clinical trial evaluating the safety and wound-healing efficacy of RGN-137 for the treatment of patients with venous stasis ulcers.
› Verified 5 days ago
Dr. Robert Paul Bertellotti, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 200 Hawkins Dr, Iowa City, IA 52242 Phone: 319-353-8435 Fax: 319-356-7850 | |
Dr. Apoorve Nayyar, MBBS Surgery Medicare: Medicare Enrolled Practice Location: 200 Hawkins Dr # Surgery, Iowa City, IA 52242 Phone: 319-356-2902 Fax: 319-356-8682 | |
Shihong Li, Surgery Medicare: Accepting Medicare Assignments Practice Location: 200 Hawkins Dr, Iowa City, IA 52242 Phone: 319-356-3396 Fax: 319-384-8114 | |
Katie Davick, Surgery Medicare: Medicare Enrolled Practice Location: 200 Hawkins Dr, Dept. Of General Surgery, Iowa City, IA 52242 Phone: 319-353-6425 Fax: 319-356-8682 | |
Dr. Darwin Dean Peterson, D.O. Surgery Medicare: Medicare Enrolled Practice Location: 540 E Jefferson St, Suite 205, Iowa City, IA 52245 Phone: 319-688-7880 Fax: 319-688-7881 | |
Jennifer C Carr, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 200 Hawkins Dr, Iowa City, IA 52242 Phone: 319-356-1616 Fax: 319-384-6004 |